

Impact of a potential PFAS-Ban on the Pharmaceutical Industry

Michael Mayr,
General Manager Fresenius Kabi Austria GmbH







#Net zero


50% reduction by 2030 and climate neutral by 2040 in our own operations, net zero by 2050



**FRESENIUS
KABI**



**FRESENIUS
KABI**





WHO ESSENTIAL DRUG



Photo credit: Fresenius



Photo credit: APA Austria



PFAS

07. Devices for administration
PFAS in pens, plasters, syringes, auto-injectors

01. Research & Development
Exemption for PPORD (product-process-orientated research and development)

06. Packaging
Polymeric PFAS content in primary packaging materials

02. Production sites
Fluoropolymers used in production facilities

05. Additives materials
Medicinal products containing PFAS as an excipient



03. Active ingredient production
Use of PFAS process chemicals for production

04. Active ingredients
Medicinal products containing PFAS as part of the active substance

07. Devices for administration
PFAS in pens, plasters, syringes, auto-
injectors are part of the authorization

01. Research & Development
Exemption for PPORD (product-process-
orientated research and development)

06. Packaging
Polymeric PFAS content in primary
packaging materials

02. PRODUCTION SITES
Fluoropolymers used in production
facilities

05. Additives materials
Medicinal products containing PFAS as an
excipient



03. Active ingredient production
Use of PFAS process chemicals for
production

04. Active ingredients
Medicinal products containing PFAS as
part of the active substance



800 seals/valves





Human Health Medicinal Products Sector Survey - Impact of Proposed PFAS Restriction on Patient Access to Medicines & EU Strategic Autonomy

Disclaimer: This document was prepared in good faith by represented associations for the purposes of preparing the public consultation response to the PFAS restriction proposed under Title VII of the REACH Regulation. The timeframe of the survey undertaken to gather the evidence was very short and companies therefore prioritised the compounds for which they would provide information with the intent to provide as much substantiated information as possible during the ECHA consultation period. The information received does not cover the full EU portfolio of the human pharmaceutical industry.


Source: Annex 2: Human Health Medicinal Products Sector Survey - Impact of Proposed PFAS Restriction on Patient Access to Medicines and EU Strategic Autonomy




64% of all medicines would be no longer available to patients!

Reshoring pharma manufacturing & battling supply chain issues

Active ingredients production by geography
(ProGenerika Study 2020)



Total notifications of supply restrictions 2011-2023
(BASG/AGES statistics)





PFAS BAN

RESHORING

INNOVATION

SUSTAINABILITY

DRUG SUPPLY

Disclaimer

Diese Präsentation kann Informationen über Produkte enthalten, die aufgrund eines unterschiedlichen Registrierungsstatus nicht in allen Ländern erhältlich sind. Daher ist immer der Text der national registrierten und zugelassenen Produktinformationen verbindlich.

Diese Präsentation enthält zukunftsgerichtete Aussagen, die verschiedenen Risiken und Ungewissheiten unterworfen sind. Die zukünftigen Ergebnisse und Entwicklungen können erheblich von den zur Zeit erwarteten Ergebnissen abweichen, und zwar aufgrund verschiedener Risikofaktoren und Ungewissheiten wie zum Beispiel Veränderungen der Geschäfts-, Wirtschafts-, und Wettbewerbssituation, Gesetzesänderungen, Ergebnisse klinischer Studien, Wechselkursschwankungen, Ungewissheiten bezüglich Rechtsstreitigkeiten oder Untersuchungsverfahren und die Verfügbarkeit finanzieller Mittel. Fresenius Kabi übernimmt keine Verpflichtung, die in dieser Präsentation enthaltenen zukunftsgerichteten Aussagen zu aktualisieren.

Herausgegeben und veröffentlicht von:

Fresenius Kabi Austria GmbH
Hafnerstraße 36, 8055 Graz

Geschäftsführung

Mag. (FH) Michael Mayr
Geschäftsführer
E michael.mayr@fresenius-kabi.com
P +43 (0) 316 249-1437

Dr. Frank Wilgmann
Geschäftsführer
E frank.wilgmann@fresenius-kabi.com
P +43 (0) 316 249-1437

Market Access

Christoph Salmhofer, M.Sc
E christoph.salmhofer@fresenius-kabi.com
P +43 (0) 664 780 15 760

Kommunikation

Mag. Birgit Görger-St.Jörgen
E birgit.goerger@fresenius-kabi.com
P +43-(0) 316-249-1205

oder besuchen Sie uns online
<https://www.fresenius-kabi.com/de-at/>